Abstract: Objective: To evaluate the efficacy and safety of dupilumab in the treatment of adult prurigo nodularis (PN). Methods: The data of adult patients with PN who were treated with regular dupilumab for 16 weeks in our hospital from May 2021 to October 2021 were retrospectively anlyzed. The efficacy and safety were accessed using the Numerical rating scale(NRS), Dermatology Life Quality Index(DLQI), Investigator's Global Assessment (IGA),and Eczema area and severity index (EASI) at weeks 0,4,8,16. Results: A total of 28 patients were collected. After 16 weeks of treatment, the scores of NRS, DLQI, IGA and EASI of 28 patients all decreased significantly, which decreased from 8.96±0.88, 24.54±3.12, 4.00±0.67 and 39.64±10.89 at baseline to 0.96±0.88, 2.43±1.40, 0.86±0.53 and 7.10±3.68, respectively, with significant differences (Ps<0.05). Dry eye occurred in 1 patient, local injection reactions occurred in 4 patients, and no other serious adverse events occurred. Conclusion: Dupilumab can continuously improve the skin lesions and pruritus of nodular pruritus with high safety, which provide a new treatment option for PN.

Key words: prurigo nodularis, dupilumab, safety